https://www.selleckchem.com/products/tng908.html
24 ± 0.15% vs. -0.35 ± 0.11%, p less then 0.0001; glycated albumin, -4.4 ± 0.6% vs. -2.4 ± 0.5%, p less then 0.01). Body weight (-1.3 ± 0.4 kg vs. -1.5 ± 0.3 kg, p=0.69) or body fat mass/lean tissue mass; urinary albumin excretion [(median, IQR) -5.3 [-60.6, 9.9] mg/g-creatinine vs. -12.9 [-70.8, -2.0] mg/g-creatinine, p=0.23]; and frequency of hypoglycemia did not differ significantly between the groups over 24 weeks. There were no cases of study discontinuation owing to adverse effects. CONCLUSIONS Liraglutide addition to ongoing insul
Like
Comment
Share
